ImmunityBio presents Phase 3 lung cancer data on ANKTIVA-based regimen at ASCO 2026

ImmunityBio

ImmunityBio

IBRX

0.00
  • ImmunityBio flagged new data for ANKTIVA across lung and bladder cancer at the ASCO meeting running May 29 to June 2, 2026.
  • Two Phase 3 NSCLC studies will be presented in future poster sessions, testing ANKTIVA-based regimens in first-line treatment and in checkpoint-resistant disease.
  • An online ASCO abstract due May 21, 2026 will compare ANKTIVA with BCG against pembrolizumab in BCG-unresponsive NMIBC.
  • The update points to a strategy of restoring immune competence to support checkpoint inhibitor responses, extending ANKTIVA’s commercial narrative beyond bladder cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260601924208) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.